 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7457 News |  |
| «12...86878889909192939495969798» |
- Zomacton (somatropin) / Ferring
Enrollment open, Combination therapy: ZomaTrip: A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (clinicaltrials.gov) - Aug 8, 2014
P4, N=30, Recruiting, Sponsor: Belgian Study Group for Pediatric Endocrinology
Active, not recruiting --> Recruiting
- || Euflexxa (hyaluronic acid) / Ferring
Trial primary completion date: Effectiveness Trial for Evaluating IAHA for PFPS (clinicaltrials.gov) - Jul 30, 2014
P4, N=68, Recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Recruiting Trial primary completion date: May 2014 --> May 2015
- || Milprosa (progesterone vaginal ring) / Ferring
Enrollment closed: A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women (clinicaltrials.gov) - Jul 30, 2014
P1, N=56, Active, not recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Trial primary completion date: May 2014 --> May 2015 Recruiting --> Active, not recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date, HEOR: RA-PROACTIVE: Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=145, Active, not recruiting, Sponsor: UCB, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Nov 2015
- |||| Hernicore (condoliase) / Seikagaku, Ferring
Trial primary completion date: A Study of SI-6603 in Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Jul 23, 2014
P3, N=360, Recruiting, Sponsor: Seikagaku Corporation
Trial primary completion date: Jan 2015 --> Nov 2015 Trial primary completion date: Dec 2014 --> Oct 2015
- ||| Zomacton (somatropin) / Ferring
Enrollment open, Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=90, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Dec 2014 --> Oct 2015 Not yet recruiting --> Recruiting
- ||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=315, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Menopur (menotropin) / Ferring
Trial completion: SHOview: Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old. (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=455, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia (clinicaltrials.gov) - Jul 14, 2014
P1b, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Sep 2018
- |||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: RAPID-C: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 12, 2014
P3, N=400, Recruiting, Sponsor: UCB Pharma SA, Belgium
Trial primary completion date: Jul 2017 --> Sep 2018 Not yet recruiting --> Recruiting
- ||| Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Enrollment change: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jul 2, 2014
P2, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting N=180 --> 120
- New P1/2 trial: Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - Jul 1, 2014
P1/2, N=30, Not yet recruiting, Sponsor: Center for Human Reproduction
- ||| Zomacton (somatropin) / Ferring
New P3 trial: A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency (clinicaltrials.gov) - Jun 26, 2014
P3, N=46, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- Cervidil (dinoprostone) / Ferring
Clinical: Oral Misoprostol Versus Vaginal Dinoprostone For Induction Of Labour: A Randomized Controlled Clinical Trial (clinicaltrials.gov) - Jun 22, 2014
P=N/A, N=342, Recruiting, Sponsor: Ain Shams University
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=500, Recruiting, Sponsor: UCB, Inc.
N=180 --> 120 Trial primary completion date: Sep 2017 --> Dec 2020
- ||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer (clinicaltrials.gov) - Jun 8, 2014
P3, N=230, Active, not recruiting, Sponsor: Astellas Pharma Inc
Trial primary completion date: Sep 2017 --> Dec 2020 Recruiting --> Active, not recruiting
- Xtandi (enzalutamide) / Pfizer, Astellas, Firmagon (degarelix) / Astellas, Ferring
New P2 trial, IO biomarker: A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy (clinicaltrials.gov) - Jun 5, 2014
P2, N=27, Not yet recruiting, Sponsor: Kenneth Pienta, MD
- Trial primary completion date: Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=43, Completed, Sponsor: Main Line Fertility Center
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2013 --> May 2014
- | Trial completion: Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=43, Completed, Sponsor: Main Line Fertility Center
Trial primary completion date: Apr 2013 --> May 2014 Recruiting --> Completed
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: RAPID-C: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 28, 2014
P3, N=400, Not yet recruiting, Sponsor: UCB Pharma SA, Belgium
- |||||||||| Testavan (transdermal testosterone gel 2%) / Ferring
New P3 trial: A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males (clinicaltrials.gov) - May 27, 2014
P3, N=142, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- |||| Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population (clinicaltrials.gov) - May 25, 2014
P3, N=280, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- ||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population (clinicaltrials.gov) - May 25, 2014
P3, N=280, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: May 2014 --> May 2015 Recruiting --> Active, not recruiting
- | Lutrelef (gonadorelin acetate) / Ferring
Trial primary completion date: LutrePulse Hypogonadotropic Hypogonadism (clinicaltrials.gov) - May 11, 2014
P3, N=36, Recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Feb 2015
- Lutrelef (gonadorelin acetate) / Ferring
Trial completion date: LutrePulse Hypogonadotropic Hypogonadism (clinicaltrials.gov) - May 11, 2014
P3, N=36, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Nov 2014 --> Feb 2015 Trial completion date: Jan 2015 --> Apr 2015
- | Milprosa (progesterone vaginal ring) / Ferring
Trial completion: Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement (clinicaltrials.gov) - May 10, 2014
P2, N=20, Completed, Sponsor: Duramed Research
Trial completion date: Jan 2015 --> Apr 2015 No longer recruiting --> Completed
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer (clinicaltrials.gov) - May 8, 2014
P2, N=100, Not yet recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial primary completion date: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
No longer recruiting --> Completed Trial primary completion date: Aug 2014 --> Apr 2014
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion date: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Aug 2014 --> Apr 2014 Trial completion date: Sep 2014 --> May 2014
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial termination: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Trial completion date: Sep 2014 --> May 2014 Suspended --> Terminated; Terminated due to a distribution issue with the trial medication
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment change: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Suspended --> Terminated; Terminated due to a distribution issue with the trial medication N=840 --> 374
- | New P4 trial: Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (clinicaltrials.gov) - May 5, 2014
P4, N=100, Recruiting, Sponsor: Jagiellonian University
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 29, 2014
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
N=840 --> 374 Trial primary completion date: Apr 2015 --> May 2015
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 29, 2014
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Trial primary completion date: Apr 2015 --> May 2015 Trial completion date: Apr 2015 --> May 2015
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial primary completion date: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Trial completion date: Apr 2015 --> May 2015 Trial primary completion date: Jun 2014 --> Mar 2014
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion date: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jun 2014 --> Mar 2014 Trial completion date: Sep 2014 --> Apr 2014
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial termination: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Trial completion date: Sep 2014 --> Apr 2014 Suspended --> Terminated; Terminated due to a distribution issue with the trial medication
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment change: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Suspended --> Terminated; Terminated due to a distribution issue with the trial medication N=840 --> 314
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - Apr 22, 2014
P1, N=34, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=840 --> 314 Not yet recruiting --> Recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=15, Completed, Sponsor: Shafran Gastroenterology Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
New P1 trial, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - Apr 21, 2014
P1, N=34, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Euflexxa (hyaluronic acid) / Ferring
Trial termination: Post-op Treatment With Hyaluronic Acid Injections (clinicaltrials.gov) - Apr 20, 2014
P4, N=33, Terminated, Sponsor: The Hawkins Foundation
Recruiting --> Completed Recruiting --> Terminated; Insurance now covers post-op HA injections, drastically decreasing enrollment.
- Euflexxa (hyaluronic acid) / Ferring
Enrollment change: Post-op Treatment With Hyaluronic Acid Injections (clinicaltrials.gov) - Apr 20, 2014
P4, N=33, Terminated, Sponsor: The Hawkins Foundation
Recruiting --> Terminated; Insurance now covers post-op HA injections, drastically decreasing enrollment. N=99 --> 33
- || Menopur (menotropin) / Ferring
Enrollment closed: SHOview: Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old. (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=450, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
N=99 --> 33 Recruiting --> Active, not recruiting
- |||||||||| Euflexxa (hyaluronic acid) / Ferring
New P3 trial, Head-to-Head: Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ (clinicaltrials.gov) - Apr 8, 2014
P3, N=418, Recruiting, Sponsor: Bioventus LLC
- Bravelle (urofollitropin) / Ferring
Enrollment open: Needle-Free Injections of Gonadotropins for Superovulation (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=60, Recruiting, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Menopur (menotropin) / Ferring
New P2/3 trial: Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF (clinicaltrials.gov) - Mar 27, 2014
P2/3, N=50, Not yet recruiting, Sponsor: University of Athens
- || Zomacton (somatropin) / Ferring
Trial initiation date, Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Jun 2014
- ||| Firmagon (degarelix) / Astellas, Ferring
Trial completion, Metastases: Effectiveness and Safety of Firmagon (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=676, Completed, Sponsor: Ferring Pharmaceuticals
Initiation date: Mar 2014 --> Jun 2014 Active, not recruiting --> Completed